No Data
No Data
Gilead's oral treatment for HIV research has achieved positive results.
Gilead announced positive results in the oral treatment research of AIDS, involving a combination treatment plan of islatravir and lenacapavir. Gilead and Merck & Co previously announced the initiation of a Phase 2 clinical study to evaluate the safety and antiviral effects of a once-weekly oral regimen consisting of islatravir and lenacapavir in HIV-1 infected adults who have achieved virologic suppression with antiretroviral therapy. The primary endpoint is HIV-1 RNA at week 24 of treatment.
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in Metastatic Urothelial Cancer
Express News | Gilead Shares Down 1% Premarket After Co to Voluntarily Withdraw Urothelial Cancer Drug in U.S.
Express News | Gilead: To Voluntarily Withdraw U.S. Accelerated Approval for Trodelvy for Treatment of Adults With Locally Advanced/Metastatic Urothelial Cancer
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
No Data
No Data